Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.
|Headquarters||New York, New York|
|Number of employees||51-200 employees|
Top 5 Recent Tweets
|April 07, 2023||urotoday||#TumorBoard Reviewing the Use of PSMA PET in the Care of Patients Who Underwent Fluciclovine for #ProstateCancer… https://t.co/53ba636jbv|
|April 06, 2023||urotoday||#TumorBoard Reviewing the Use of PSMA PET in #ProstateCancer, Gleason 4+4=8 GG 4 @HJacene @adamkibel_uro… https://t.co/OiGE36oDWX|
|April 04, 2023||urotoday||#TumorBoard Reviewing the Use of PSMA PET in #ProstateCancer -Gleason 3+4=7, GG 2 (left) Gleason 3+3=6 GG 1 (right)… https://t.co/eufTXMDvyB|